Work

68P Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and/or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx): CORRELATE

Year: 2023

Type: article

Abstract: PD-(L)1 inhibitors ± chemotherapy (CT) have demonstrated survival benefit vs CT in mNSCLC RCTs. However, STK11mut and KEAP1mut tumours have been characterised as immunologically ‘cold’ and are frequently associated with a concomitant KRASmut. One aim of CORRELATE was to describe rw outcomes of pts with mNSCLC and STK11, KEAP1 and/or KRAS mut receiving tx with anti-PD-(L)1 ± CT.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2023.100540